A manuscript titled, “Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study,” was published in the Journal of Addiction Medicine by the American Society of Addiction Medicine by authors Nicolas Garel, Kyle T. Greenway, Paola Lavin, C. William Pike, Rebecca Hyde, Didier Jutras-Aswad, Steven D. Tate, and Anna Lembke. Dr. Garel and Dr. Jutras-Aswad are affiliated with the University of Montreal, Dr. Greenway is affiliated with McGill University and Jewish General Hospital, Dr. Lavin is affiliated with McGill University, Dr. Pike and Ms. Hyde are affiliated with Atropos Health, Dr. Tate is affiliated with Stanford Medicine, and Dr. Lembke is affiliated with Stanford University.
Short Summary:
Individuals with stimulant use disorders (StSUDs) present an elevated risk of cardiovascular complications compared with the general population. A retrospective cohort study was conducted to understand whether those affected by StSUDs are at risk for higher cardiovascular complications than the larger population of individuals with substance use disorders (SUDs).
Key Conclusions:
A national dataset was analyzed and found that among patients with SUDs, those with StSUD face a 37% higher risk of MACE, including a 23% higher risk of death. Among 137,106 patients with SUD, 7,706 (5.6%) had StSUD. Stimulant users exhibited significantly higher major adverse cardiac event (MACE) rates (HR=1.37, 95% CI: 1.22-1.53, P <0.001), including an elevated risk of death (HR=1.23, 95% CI: 1.02-1.47, P =0.026).
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com